Australia Anti-infective Agents Market Size & Outlook
Australia anti-infective agents market, 2018-2030 (US$M)
Related Markets
Australia anti-infective agents market highlights
- The Australia anti-infective agents market generated a revenue of USD 1,769.3 million in 2024 and is expected to reach USD 1,932.0 million by 2030.
- The Australia market is expected to grow at a CAGR of 1.9% from 2025 to 2030.
- In terms of segment, antivirals was the largest revenue generating type in 2024.
- Antifungals is the most lucrative type segment registering the fastest growth during the forecast period.
Anti-infective agents market data book summary
| Market revenue in 2024 | USD 1,769.3 million |
| Market revenue in 2030 | USD 1,932.0 million |
| Growth rate | 1.9% (CAGR from 2025 to 2030) |
| Largest segment | Antivirals |
| Fastest growing segment | Antifungals |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antibacterials, Antivirals, Antifungals |
| Key market players worldwide | Pfizer Inc, Abbott Laboratories, Gilead Sciences Inc, Bristol-Myers Squibb Co, Merck & Co Inc, Sandoz Group AG ADR, B. Braun, Novo Holdings, Mankind Pharma, Bayer AG, AstraZeneca PLC, Boehringer Ingelheim Pharma |
Other key industry trends
- In terms of revenue, Australia accounted for 1.3% of the global anti-infective agents market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China anti-infective agents market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 8,841.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anti-infective Agents Market Scope
Anti-infective Agents Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia anti-infective agents market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-infective agents market will help companies and investors design strategic landscapes.
Antivirals was the largest segment with a revenue share of 45.81% in 2024. Horizon Databook has segmented the Australia anti-infective agents market based on antibacterials, antivirals, antifungals covering the revenue growth of each sub-segment from 2018 to 2030.
The anti-infective agents market in Australia is experiencing notable growth, supported by active research and international collaboration. In September 2022, researchers from the University of Bern and the University of Queensland collaborated internationally to reveal that chemical compounds with specific metals can be highly effective against severe fungal infections.
Additionally, in October 2024, Shanghai MicuRx Pharmaceutical Co., Ltd. announced the successful completion of a Phase I clinical trial in Australia for MRX-5, an innovative oral antibacterial agent designed to treat nontuberculous mycobacterial (NTM) infections. These advancements highlight Australia's role in pioneering antiinfective research and clinical progress.
Reasons to subscribe to Australia anti-infective agents market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia anti-infective agents market databook
-
Our clientele includes a mix of anti-infective agents market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia anti-infective agents market , including forecasts for subscribers. This country databook contains high-level insights into Australia anti-infective agents market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia anti infective agents market size, by type, 2018-2030 (US$M)
Australia Anti-infective Agents Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
